4 completed, 2 unknown, 1 recruiting, 1 terminated. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease Kisspeptin 112-121 - Reproductive Disorder, Neurodegeneration | Phase 1 | Recruiting | Stephanie B. Seminara, MD | 40 | 2026-03-10 | 2026-07-13 |
| Fase I Clinical Trial on NK Cells for COVID-19 Natural Killer Cells infusion - Covid19, Sars-cov 2 | Phase 1 | Unknown | Hospital de Clinicas de Porto Alegre | 24 | 2021-01-02 | 2020-11-18 |
| Anti-SARS Cov-2 T Cell Infusions for COVID 19 Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs) - SARS-CoV 2, Viral Infection | Phase 1 | Terminated | Baylor College of Medicine | 4 | 2020-11-04 | 2022-12-19 |
| Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer - Coronavirus Infection, SARS-CoV 2 | Phase 1 / Phase 2 | Completed | International Vaccine Institute | 79 | 2020-07-15 | 2022-07-18 |
| Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. Intramuscular Vaccine - SARS-CoV 2 | Phase 1 | Completed | Medicago | 180 | 2020-07-10 | 2022-04-06 |
| CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 convalescent plasma - COVID-19, SARS-CoV 2 | Phase 1 / Phase 2 | Unknown | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | 90 | 2020-05-20 | 2020-06-05 |
| Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 XCEL-UMC-BETA, Placebo - COVID-19, SARS-CoV 2 | Phase 1 / Phase 2 | Completed | Banc de Sang i Teixits | 26 | 2020-05-13 | 2023-01-26 |
| Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection Hyperimmune plasma, Standard of care for SARS-CoV-2 infection - SARS-CoV 2 | Phase 1 / Phase 2 | Completed | Andalusian Network for Design and Translation of Advanced Therapies | 72 | 2020-04-23 | 2022-04-06 |
COVID-19 (4) · Convalescence (1) · Coronavirus Infections (1) · Nerve Degeneration (1) · Post-Acute COVID-19 Syndrome (1) · Respiratory Distress Syndrome (1) · Virus Diseases (1)
Coronaviridae Infections (6) · Infections (6) · Nidovirales Infections (6) · RNA Virus Infections (6) · Coronavirus Infections (5) · Lung Diseases (5) · Pneumonia (5) · Pneumonia, Viral (5) · Respiratory Tract Diseases (5) · Respiratory Tract Infections (5) · Virus Diseases (5) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · COVID-19 (1)
Buffers (1) · COVID-19 Serotherapy (1) · Maximum Tolerated Dose (1) · Standard of Care (1) · reluscovtogene ralaplasmid (1)
Andalusian Network for Design and Translation of Advanced Therapies (1) · Banc de Sang i Teixits (1) · Baylor College of Medicine (1) · Hospital de Clinicas de Porto Alegre (1) · Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (1) · International Vaccine Institute (1) · Medicago (1) · Stephanie B. Seminara, MD (1)
Spain (2) · United States (2) · Brazil (1) · Canada (1) · Mexico (1) · South Korea (1)
Antoni Torres, MD, PhD (1) · Brian J Ward, MD (1) · Eu Suk Kim, MD (1) · Lucia Silla, MD, PhD (1) · Luis M Villela, MD (1) · Myoung-don Oh, MD (1) · Premal Lulla (1)
PMID 11023960, PMID 20370679, PMID 25457751, PMID 32125452, PMID 32219428, PMID 34007070, PMID 36373249, PMID 3898484
R37HD043341 (1)